Holding: In Genentech, Inc. v. Aurobindo
Pharma Limited, No. 19-cv-78-RGA, 2020 WL 6144696, (D. Del.
Oct. 20, 2020), United States District Court for the District of
Delaware (Judge Richard G. Andrews) held that the term "Grade
2 abnormality in one or more biomarkers of liver function," as
recited in three asserted patents, U.S. Pat. Nos. 7,566,729;
7,635,707; and 8,592,462, is not indefinite, and adopted
Plaintiffs' proposed claim construction.
Background: Plaintiffs Genentech and InterMune
brought a Hatch-Waxman patent infringement action against various
generic pharmaceutical companies. Id. at *2. The case
turned on the construction of the claim term "Grade 2
abnormality in one or more biomarkers of liver function," as
recited in various asserted claims of the three asserted patents.
Id.